Large Molecule / Generic

Novartis Keeps Fighting for Neupogen Biosimilar

Jun 04, 2015

Reuters

Novartis' Sandoz unit asked a U.S. appeals court to lift a preliminary injunction barring it from selling its biosimilar Zarxio, a cheaper version of Amgen's cancer blockbuster, Neupogen.

Last month, the U.S. Court of Appeals for the Federal Circuit granted a preliminary injunction barring the sale of Zarxio while the two companies worked through a patent lawsuit.

A panel will decide whether Sandoz made appropriate disclosures to Amgen that it planned to produce a copy of Neupogen -- as the law requires. Amgen argues Sandoz failed to follow regulations about how notice is to be given regarding the launch of a biosimilar.

Read the Reuters article